DaVita Inc. (NYSE:DVA) Shares Sold by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. reduced its position in DaVita Inc. (NYSE:DVA - Free Report) by 7.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,594 shares of the company's stock after selling 2,196 shares during the quarter. Nomura Asset Management Co. Ltd.'s holdings in DaVita were worth $3,977,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. FMR LLC boosted its stake in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company's stock worth $29,082,000 after purchasing an additional 154,061 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of DaVita by 16.6% during the third quarter. Captrust Financial Advisors now owns 3,992 shares of the company's stock worth $654,000 after buying an additional 569 shares during the period. Verition Fund Management LLC grew its holdings in shares of DaVita by 313.6% during the third quarter. Verition Fund Management LLC now owns 9,603 shares of the company's stock valued at $1,574,000 after buying an additional 7,281 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of DaVita in the 3rd quarter valued at $1,820,000. Finally, Erste Asset Management GmbH purchased a new position in DaVita in the 3rd quarter worth $454,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DVA shares. StockNews.com downgraded DaVita from a "buy" rating to a "hold" rating in a research note on Wednesday. Cowen reiterated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays raised their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $166.33.

Remove Ads

DaVita Stock Performance

NYSE:DVA traded down $4.37 during trading hours on Friday, reaching $149.37. The company had a trading volume of 1,009,511 shares, compared to its average volume of 810,838. The firm has a market cap of $11.95 billion, a PE ratio of 13.91, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The business's 50 day moving average price is $156.16 and its 200-day moving average price is $157.39. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.